Advanced Biomed Inc. Common Stock Price & Performance (ADVB)

Impact BioMedical Inc.'s 180-day lock-up agreement concluded on March 15, 2025. This restriction had prevented key stakeholders from selling shares, potentially limiting market activity. With the expiration, trading volume may increase as these shares become available, a development that could influence the company's stock performance in the coming weeks.1

Advanced Biomed Inc. successfully closed its IPO on March 7, 2025, raising $6.56 million. Shares are now trading on Nasdaq under the ticker 'ADVB.' The funds will support cancer diagnostic research, market expansion, and working capital. This milestone positions the company for growth in global healthcare markets.23

Checkpoint Therapeutics saw a 66% pre-market stock surge following Sun Pharma's acquisition announcement valued at $355 million. This strategic move bolsters Sun Pharma's oncology portfolio while offering Checkpoint Therapeutics shareholders a significant premium, reflecting confidence in its cancer treatment pipeline.4